Severe Myelosuppression
- Do not administer ABRAXANE therapy to patients who have baseline neutrophil counts of less than 1,500 cells/mm3.
Monitoring data
- Monitor for neutropenia, which may be severe and result in infection or sepsis, it is recommended that frequent.
- Perform frequent complete blood cell counts on all patients receiving ABRAXANE
Package inserts
Updated: January 2023